Till startsida
To content Read more about how we use cookies on gu.se

Peter Bernhardt

Professor/ medical physicist

Peter Bernhardt
Professor/ medical physicist
+46 31-342 8509

Postal Address: Sahlgrenska universitetssjukhuset, 41345 Göteborg
Visiting Address: Jubileumskliniken, blå stråket 2 , 41345 Göteborg

Department of Radiation Physics at Institute of Clinical Sciences (More Information)
Sahlgrenska Universitetssjukhuset
413 45 Göteborg
Visiting Address: Gula stråket 2 B SU/Sahlgrenska , 413 45 Göteborg

Latest publications

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
C. Muller, C. A. Umbricht, N. Gracheva, V. J. Tschan, G. Pellegrini et al.
European Journal of Nuclear Medicine and Molecular Imaging, Journal article 2019
Journal article

Establishment of Optimized SPECT/CT Protocol for Therapy with 161Tb Demonstrate Improved Image Quality with Monte Carlo Based OSEM Reconstruction
Ida Marin, Tobias Rydén, Martijn van Essen, Johanna Svensson, N. Van der Meulen et al.
31st Annual Congress of the EANM, Conference contribution 2018
Conference contribution

Feasibility of simplifying renal dosimetry in Lu-177 peptide receptor radionuclide therapy
A. Sundlov, J. Gustafsson, G. Brolin, N. Mortensen, Rebecka Hermann et al.
Ejnmmi Physics, Journal article 2018
Journal article

Monte Carlo Based SPECT Activity Quantification and Tumor Dosimetry for 177Lu-DOTATATE Treatments
Ida Marin, Johanna Svensson, Tobias Rydén, Emma Wikberg, Anna-Karin Elf et al.
30th Annual Congress of the European Association of Nuclear Medicine, Poster 2017

Showing 61 - 70 of 104


Absorbed dose to the kidneys after treatment with 177Lu-octreotate
Maria Larsson, Peter Bernhardt, Eva Forssell-Aronsson
European Association of Nuclear Medicine Congress. Birmingham, Conference paper 2011
Conference paper

Assessment of tumour response to therapy
Esmaeil Mehrara, Peter Bernhardt, Eva Forssell-Aronsson
European Association of Nuclear Medicine Congress. Birmingham, Conference paper 2011
Conference paper


Modelling the systemic cure in radionuclide therapy.
Peter Bernhardt, Speer
Targeted radionuclide therapy.Speer T (Eds), Lippincott Williams & Wilkins, Chapter in book 2010
Chapter in book

Exendin-4-Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT
Damian Wild, Andreas Wicki, Rosalba Mansi, Martin Behe, Boris Keil et al.
Journal article


Production of Rh-103m for cancer therapy
Gunnar Skarnemark, Arvid Ödegaard-Jensen, J. Nilsson, B. Bartos, E. Kowalska et al.
Journal of Radioanalytical and Nuclear Chemistry, Journal article 2009
Journal article

Showing 61 - 70 of 104

Page Manager: Johan Spetz|Last update: 11/20/2013

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?